Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.CELZ · Entity 8127 | Director · CFO & Sr. VP | February 09, 2022 | February 11, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Report date February 09, 2022 · Filed February 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2032-02-09 | Direct | 53,237 |
Reported balance
After 2022-02-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-09 · Grant · Acquired 53,237 · Balance 53,237 F1: The options vests immediately as to 25% of the shares subject to the option, and in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vests immediately as to 25% of the shares subject to the option, and in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2022 Filed Feb 11, 2022 17:00 UTC | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CELZ · Entity 8127 | GrantStock Option (Right to Buy) · Derivative | 53,237 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001477932-22-000692 · form4.xml · derivative · entry 1 Dickerson Donald · CIK 0001674942 · Director · CFO & Sr. VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,237 Underlying: Common Stock · 53,237 shares Expires 2032-02-09 F1 · derivative.exercise_date: The options vests immediately as to 25% of the shares subject to the option, and in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 16:30 UTC | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CELZ · Entity 8127 | GrantWarrant to Purchase Common Stock · Derivative | 5,000,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001477932-21-004705 · form4.xml · derivative · entry 1 Dickerson Donald · CIK 0001674942 · Director · CFO & Sr. VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000,000 Underlying: Common Stock · 5,000,000 shares Expires 2031-07-15 Read SEC document |
| December 28, 2020 Filed Dec 31, 2020 16:30 UTC | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CELZ · Entity 8127 | GrantWarrant to Purchase Common Stock · Derivative | 10,000,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001477932-20-007595 · form4.xml · derivative · entry 1 Dickerson Donald · CIK 0001674942 · Director · CFO & Sr. VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000,000 Underlying: Common Stock · 10,000,000 shares Expires 2030-12-28 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.